China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)

SHE:300294 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,734	2,651	2,761	2,645	2,510
Other Revenue	0.79	0.85	-2.22	5.21	3.36
Revenue	1,735	2,652	2,759	2,651	2,513
Revenue Growth (YoY)	-34.58%	-3.87%	4.08%	5.47%	-13.61%
Cost of Revenue	615.97	1,259	1,255	1,187	1,055
Gross Profit	1,119	1,393	1,504	1,463	1,458
Selling, General & Admin	603.65	774.85	923.64	969.52	1,039
Research & Development	66.89	67.7	49.58	59.29	89.05
Other Operating Expenses	17.47	18.98	20.83	19.99	8.93
Operating Expenses	696.81	863.9	996.86	1,049	1,128
Operating Income	422.12	529.38	507.16	414.49	330.18
Interest Expense	-0.66	-0.46	-0.62	-10.53	-21.45
Interest & Investment Income	42.49	45.31	64.93	63.9	22.96
Currency Exchange Gain (Loss)	-2.77	-	-	-	-
Other Non Operating Income (Expenses)	0.87	-0.43	4.02	-8.3	-3.07
EBT Excluding Unusual Items	462.05	573.81	575.49	459.57	328.63
Impairment of Goodwill	-72.61	-298.41	-	-	-
Gain (Loss) on Sale of Investments	65.58	85.74	-	10.71	-
Gain (Loss) on Sale of Assets	-0.61	1.3	0.07	-0.87	-1.58
Asset Writedown	-11.18	-28.31	-51.03	-36.37	-0.27
Other Unusual Items	34.49	19.59	7.47	10.08	1.36
Pretax Income	477.71	353.71	532	443.12	328.13
Income Tax Expense	81.19	105.56	86.51	84.84	52.87
Earnings From Continuing Operations	396.53	248.15	445.49	358.28	275.26
Minority Interest in Earnings	0.46	-10.68	-13.29	-13.75	-15.2
Net Income	396.99	237.47	432.2	344.53	260.06
Net Income to Common	396.99	237.47	432.2	344.53	260.06
Net Income Growth	67.18%	-45.06%	25.45%	32.48%	-38.97%
Shares Outstanding (Basic)	503	505	503	436	426
Shares Outstanding (Diluted)	503	505	503	436	426
Shares Change (YoY)	-0.54%	0.53%	15.24%	2.30%	0.04%
EPS (Basic)	0.79	0.47	0.86	0.79	0.61
EPS (Diluted)	0.79	0.47	0.86	0.79	0.61
EPS Growth	68.08%	-45.35%	8.86%	29.51%	-39.00%
Free Cash Flow	101.99	554.23	458.03	1,277	576.07
Free Cash Flow Per Share	0.20	1.10	0.91	2.93	1.35
Dividend Per Share	0.320	0.300	0.200	0.150	0.065
Dividend Growth	6.67%	50.00%	33.33%	130.77%	-56.67%
Gross Margin	64.50%	52.54%	54.52%	55.21%	58.01%
Operating Margin	24.33%	19.96%	18.38%	15.64%	13.14%
Profit Margin	22.88%	8.95%	15.67%	13.00%	10.35%
Free Cash Flow Margin	5.88%	20.90%	16.60%	48.19%	22.92%
EBITDA	519.84	624.38	600.38	510.65	411.52
EBITDA Margin	29.96%	23.54%	21.76%	19.27%	16.38%
D&A For EBITDA	97.71	94.99	93.22	96.16	81.34
EBIT	422.12	529.38	507.16	414.49	330.18
EBIT Margin	24.33%	19.96%	18.38%	15.64%	13.14%
Effective Tax Rate	16.99%	29.84%	16.26%	19.15%	16.11%
Revenue as Reported	1,735	2,652	2,759	2,651	-
Advertising Expenses	3.26	2.73	1.82	2.5	1.77

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.